Investigational muvalaplin (Eli Lilly), the first oral therapy being developed to lower lipoprotein (a) levels, was shown to reduce levels in a phase 1 trial, with no safety concerns, researchers ...
Muvalaplin, an oral drug, significantly reduces Lp(a) levels by disrupting apo(a) and apoB bonding, achieving up to 85.5% reduction in a phase 2 study. Lp(a) is a genetically driven cardiovascular ...
A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the ...
Eli Lilly (LLY) and Company announced “positive” Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a), or Lp(a), a genetically ...
Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal of ...
Muvalaplin, a novel oral medication, safely and effectively lowers high levels of lipoprotein(a), or Lp(a), results from the phase 2 KRAKEN trial show. Concentrations of Lp(a) cholesterol are ...
"While muvalaplin appears to be an effective approach to lowering Lp (a) levels, we still need to study whether Lp (a) lowering will result in fewer heart attacks and strokes." The study had ...
Lipoprotein(a) has been linked to aortic stenosis and atherosclerosis. Lipoprotein(a) is formed by the interaction of apolipoprotein(a) with apolipoprotein B100. Muvalaplin, a small molecule drug, ...
On 18 November 2024, at the American Heart Association's (AHA) 2024 conference in Chicago, Illinois, US, during a late-breaking session on the topic of New Targets and New Treatments: Advances in ...
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...
The oral medication muvalaplin may safely lower high levels of lipoprotein(a), also known as Lp(a), an independent, inherited risk factor for cardiovascular disease. Muvalaplin is a small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results